Dr. Jeffrey Whitten brings to
CalciMedica more than twenty-five years of experience in the pharmaceutical
and biotechnology industries. Previously, he served as Vice President
of Research at Cylene, Director of Chemistry at Neurocrine, Group
Leader at Marion Merrell Dow (now Aventis) and as a chemist at
Glaxo Pharmaceuticals and Sandoz (now Novartis). He has been responsible
for the discovery and development of numerous clinical candidates
for a variety of diseases and has also worked on the teams that
brought Allegra and Albutamol to the market.
Dr. Whitten received his scientific
education in England at Manchester and Oxford Universities for
his B. Sc. and Ph.D., respectively. As a Research Fellow, he worked
with Sir Jack Baldwin at Oxford University on the interface of
synthesis and biology. His continuing interest in the application
of this technology to drug discovery has resulted in over 250
patents and publications. Dr. Whitten also received an MBA in
Corporate Finance and Marketing from Ohio State University.
